Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Head and Neck Squamous Cell Carcinoma: Update Bulletin [May 2016]

Product Code:
596200544
Publication Date:
April 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of head and neck squamous cell carcinoma (HNSCC). Topics covered include opinions about the US FDA priority review granted for Merck & Co.’s Keytruda (pembrolizumab) for its application for the treatment of HNSCC. The application concerns the treatment of patients with recurrent or metastatic HNSCC whose disease has progressed on, or after, platinum-based chemotherapy. KOL opinion is also presented on the recent FDA breakthrough therapy designation granted for Bristol-Myers Squibb’s Opdivo (nivolumab). This designation is based on data from the Phase III CheckMate-0141 trial of nivolumab, which were recently presented at the American Association for Cancer Research (AACR) annual meeting.

Business Questions

  • How do KOLs view the recent allocation of FDA priority review status to Merck & Co.’s Keytruda in HNSCC
  • How convincing is the case for FDA approval of Merck & Co.’s Keytruda for the treatment of HNSCC?
  • How do KOLs view the ORR, duration of response and tolerability profile for Merck & Co.’s Keytruda in the second-line setting?
  • How likely is it that PD-1 inhibitors will become the second-line standard of care in HNSCC treatment?
  • Will Merck & Co.’s Keytruda face any significant barriers to adoption?
  • How do KOLs view the recent FDA breakthrough therapy designation for Bristol-Myers Squibb’s Opdivo in HNSCC?
  • How effective will Bristol-Myers Squibb’s Opdivo be in driving better patient outcomes?
  • How do Merck & Co.’s Keytruda and Bristol-Myers Squibb’s Opdivo compare in terms of convenience when administered as HNSCC therapies?
  • How do Merck & Co.’s Keytruda and Bristol-Myers Squibb’s Opdivo compare in terms of clinical profile, and what factors could influence their relative success in HNSCC?
  • How big an advantage will be garnered by the first PD-1 inhibitor to be approved for the treatment of HNSCC?



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved